Breaking Finance News

Zacks Investment Research downgraded SCYNEXIS Inc (NASDAQ:SCYX) to Hold in a report released today.

Yesterday SCYNEXIS Inc (NASDAQ:SCYX) traded 0.44% higher at $1.66. The company’s 50-day moving average is $2.19 and its 200-day moving average is $2.04. The last stock close price is down 11.77% from the 200-day moving average, compared to the S&P 500 which has increased 0.03% over the same time. 234,840 shares of the stock were exchanged, down from an average trading volume of 254,098

Zacks Investment Research has downgraded SCYNEXIS Inc (NASDAQ:SCYX) to Hold in a report released on 6/08/2017.

See Chart Below


SCYNEXIS Inc has a 52 week low of $1.52 and a 52 week high of $4.21 The company’s market cap is currently $0.

In addition to Zacks Investment Research reporting its target price, a total of 5 analysts have released a report on SCYNEXIS Inc. The 12-month price target is $14.40 with one analyst rating the company a strong buy, 4 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell.

Brief Synopsis On SCYNEXIS Inc (NASDAQ:SCYX)

SCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains. The Company also conducts additional in vitro and in vivo studies to further characterize the spectrum of activity of SCY-078. The Company has completed multiple Phase I studies with the oral formulation of SCY-078 and is conducting its first Phase I study with the IV formulation of SCY-078. The Company has also developed a platform for cyclophilin inhibitors, which has two clinical stage compounds, such as SCY-635 and SCY-641.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.